Evidence map›Paper›PMID 32754865›Full record

ArticlePathology oncology research : POR2020

Prevalence of APC and PTEN Alterations in Urachal Cancer.

Nikolett Nagy, Henning Reis, Boris Hadaschik, Christian Niedworok, Orsolya Módos, Attila Szendrői, Krisztina Bíró, Thomas Hager, Thomas Herold, Jason Ablat and 17 more

Open access · hybridAbstract read
In one paragraph

Article in Pathology oncology research : POR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 3 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 3 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Urachal Carcinomas: A Comprehensive Systematic Review and Meta-analysis.International braz j urol : official journal of the Brazilian Society of Urology
    Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 10 institutions in 4 countries.

Nikolett NagyDepartment of Urology, Semmelweis University, Budapest, 1082, Hungary.
Henning ReisInstitute of Pathology, West German Cancer Center, University of Duisburg-Essen, University Hospital Essen, 45147, Essen, Germany.
Boris HadaschikDepartment of Urology, West German Cancer Center, University of Duisburg-Essen, University Hospital Essen, 45147, Essen, Germany.
Christian NiedworokDepartment of Urology, West German Cancer Center, University of Duisburg-Essen, University Hospital Essen, 45147, Essen, Germany.
Orsolya MódosDepartment of Urology, Semmelweis University, Budapest, 1082, Hungary.
Attila SzendrőiDepartment of Urology, Semmelweis University, Budapest, 1082, Hungary.
Krisztina BíróNational Institute of Oncology, Budapest, 1122, Hungary.
Thomas HagerInstitute of Pathology, West German Cancer Center, University of Duisburg-Essen, University Hospital Essen, 45147, Essen, Germany.
Thomas HeroldInstitute of Pathology, West German Cancer Center, University of Duisburg-Essen, University Hospital Essen, 45147, Essen, Germany.
Jason AblatVancouver Prostate Centre, University of British Columbia, Vancouver, V6H 3Z6, Canada.
Peter C BlackVancouver Prostate Centre, University of British Columbia, Vancouver, V6H 3Z6, Canada.
Krzysztof OkonDepartment of Pathomorphology, Jagiellonian University, 30252, Cracow, Poland.
Yuri TolkachInstitute of Pathology, University of Bonn, 53113, Bonn, Germany.
Anita CsizmarikDepartment of Urology, Semmelweis University, Budapest, 1082, Hungary.
Csilla OláhDepartment of Urology, Semmelweis University, Budapest, 1082, Hungary.
David KeresztesDepartment of Urology, Semmelweis University, Budapest, 1082, Hungary.
Felix BremmerInstitute of Pathology, University of Göttingen, 37073, Göttingen, Germany.
Nadine T GaisaInstitute of Pathology, RWTH Aachen University, 52074, Aachen, Germany.
Joerg KriegsmannCytology and Molecular Diagnostics Trier, Center for Histology, 54296, Trier, Germany.
Ilona Kovalszky1st Institute of Pathology and Expreimental Cancer Research, Semmelweis University, Budapest, 1085, Hungary.
András Kiss2nd Department of Pathology, Semmelweis University, Budapest, 1091, Hungary.
József Tímár2nd Department of Pathology, Semmelweis University, Budapest, 1091, Hungary.
Marcell A SzászCancer Center, Semmelweis University, Budapest, 1083, Hungary.
Michael RinkDepartment of Urology, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.
Margit FischDepartment of Urology, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.
Péter NyirádyDepartment of Urology, Semmelweis University, Budapest, 1082, Hungary.
Tibor SzarvasDepartment of Urology, Semmelweis University, Budapest, 1082, Hungary. sztibusz@gmail.com.ORCID http://orcid.org/0000-0002-6321-0799
Semmelweis University · HUEssen University Hospital · DEUniversität Hamburg · DEUniversity of British Columbia · CAJagiellonian University · PLNational Institute of Oncology · HURWTH Aachen University · DEUniversität Trier · DEUniversity of Bonn · DEUniversity of Göttingen · DE

Funding

Nemzeti Kutatási, Fejlesztési és Innovaciós Alap (HU) NKFIH / PD 115616Nemzeti Versenyképességi és Kiválósági Program 16-1-2016-004
6 · The paper itself

Abstract

Urachal carcinoma (UrC) is a rare tumor with remarkable histological and molecular similarities to colorectal cancer (CRC). Adenomatous polyposis coli (APC) is the most frequently affected gene in CRC, but the prevalence and significance of its alterations in UrC is poorly understood. In addition, loss of phosphatase and tensin homologue (PTEN) was shown to be associated with therapy resistance in CRC. Our primary aim was to assess specific genetic alterations including APC and PTEN in a large series of UrC samples in order to identify clinically significant genomic alterations. We analyzed a total of 40 UrC cases. Targeted 5-gene (APC, PTEN, DICER1, PRKAR1A, TSHR, WRN) panel sequencing was performed on the Illumina MiSeq platform (n = 34). In addition, ß-catenin (n = 38) and PTEN (n = 30) expressions were assessed by immunohistochemistry. APC and PTEN genes were affected in 15% (5/34) and 6% (2/34) of cases. Two of five APC alterations (p.Y1075*, p.K1199*) were truncating pathogenic mutations. One of the two PTEN variants was a pathogenic frameshift insertion (p.C211fs). In 29% (11/38) of samples, at least some weak nuclear ß-catenin immunostaining was detected and PTEN loss was observed in 20% (6/30) of samples. The low prevalence of APC mutations in UrC represents a characteristic difference to CRC. Based on APC and ß-catenin results, the Wnt pathway seems to be rarely affected in UrC. Considering the formerly described involvement of PTEN protein loss in anti-EGFR therapy-resistance its immunohistochemical testing may have therapeutic relevance.

Indexed as

MutationAdenocarcinomaAdenomatous Polyposis Coli ProteinAdultAgedbeta CateninBiomarkers, TumorCystectomyFemaleFollow-Up StudiesHumansMaleMiddle AgedPrevalencePrognosisPTEN PhosphohydrolaseAdenomatous Polyposis Coli ProteinAPC protein, humanbeta CateninBiomarkers, TumorPTEN PhosphohydrolasePTEN protein, humanAPCColorectal cancerMolecular geneticsMutationß-cateninUrachal cancer

Identifiers

PMID32754865
PMCPMC7471184
OpenAlexW3047388575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.